In contrast, in patients with breast cancer, pancreatic cancer, cutaneous T-cell lymphoma, and lung cancer, elevated CCL18 in cancer tissues or body fluid indicates a worse clinical outcome [14, 23–25]. This evidence concerns the gene CCL18 and lung carcinoma.